尼尔塞维玛布对住院婴儿呼吸道共囊病毒支气管炎的影响:现实世界研究
Eric Jeziorski1,2, Antoine Ouziel1,3, Marie Cotillon1,4
1Groupe de Pathologie Infectieuse Pediatrique (GPIP), Creteil.
The Pediatric infectious disease journal
|November 26, 2024
概括
尼尔塞维马布免疫显著减少呼吸道同胞病毒 (RSV) 支气管炎在婴儿的住院治疗. 接种疫苗的婴儿经历的疾病不那么严重,需要更少的氧气和更短的住院时间,突出了nirsevimab.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 支气管炎是婴儿常见的呼吸道感染.
- 呼吸道综合体病毒 (RSV) 是婴儿支气管炎的主要原因.
- 有效的RSV预防措施至关重要.
研究的目的:
- 评估nirsevimab免疫接种在预防和减少RSV支气管炎住院治疗的严重性方面的有效性.
- 评估nirsevimab对需要补充氧气和住院时间的影响.
主要方法:
- 对1085名因支气管炎住院的婴儿进行了回顾性分析.
- 医院住院几率和临床结果的比较. 在nirsevimab免疫和非免疫婴儿之间.
主要成果:
- 没有接种疫苗的婴儿因RSV支气管炎住院的几率高4.7倍.
- 接种疫苗的婴儿不太可能需要补充氧气 (20.2%对30.6%,P = 0.02).
- 接种了nirsevimab的婴儿在医院停留时间缩短了一天.
结论:
- 尼尔塞维马布免疫与RSV支气管炎住院的频率和严重性降低有关.
- 尼尔西维马布在婴儿中提供了对严重RSV疾病的显著保护.
- 用nirsevimab接种疫苗可以改善临床结果,并减少医疗保健资源的利用.
更多相关视频
相关概念视频
Acute Respiratory Failure-II
174
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
174
Acute Respiratory Failure-I
173
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
173
Acute Respiratory Failure-V
123
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123
Acute Respiratory Failure-III
159
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
159
Acute Respiratory Failure-IV
126
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
126
Pneumonia IV: Management
299
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
299


